Stockscreener 앱 받기
6.34
9.04%
-0.63
시간 외 거래:
6.30
-0.04
-0.63%
전일 마감가:
$6.97
열려 있는:
$6.99
하루 거래량:
3.63M
Relative Volume:
2.24
시가총액:
$541.73M
수익:
$27.10M
순이익/손실:
$-24.31M
주가수익비율:
-7.6386
EPS:
-0.83
순현금흐름:
$-33.33M
1주 성능:
-46.54%
1개월 성능:
-32.55%
6개월 성능:
-67.82%
1년 성능:
+16.97%
1일 변동 폭
$6.27
$7.10
1주일 범위
$6.27
$11.32
52주 변동 폭
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
CAPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.34 | 541.73M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Shareholders that lost money on Capricor Therapeutics, Inc. (CAPR) should contact Levi & Korsinsky about Securities Fraud InvestigationCAPR - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cable One, Inc. - GlobeNewswire Inc.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet - simplywall.st
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Capricor Therapeutics, Inc. (CAPR) - ACCESS Newswire
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
How the (CAPR) price action is used to our Advantage - news.stocktradersdaily.com
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Benzinga
Capricor falls 12% as FDA orders panel to discuss Duchenne cardiomyopathy asset - MSN
Capricor Therapeutics to Present First Quarter 2025 Financial Re - GuruFocus
Capricor Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on May 13 - Nasdaq
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 - GlobeNewswire
Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting for Duchenne Treatment | CAPR Stock News - GuruFocus
FDA adcomm will review Capricor's cell therapy for Duchenne muscular dystrophy - Endpoints News
US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy - Reuters
Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting, Shares Drop - GuruFocus
Capricor Therapeutics Shares Fall as FDA Plans Panel Review for Duchenne Treatment - marketscreener.com
Capricor Share Slide 12% as FDA Calls Advisory Panel for Duchenne Cardiomyopathy Therapy - paginasiete.bo
Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic - Asianet Newsable
Capricor falls after FDA to hold advisory meeting for cell therapy - TradingView
Capricor Therapeutics (CAPR) Anticipates Positive FDA Review Despite Stock Dip | CAPR Stock News - GuruFocus
CAPR: Capricor Therapeutics Advances FDA Review for Deramiocel | CAPR Stock News - GuruFocus
Capricor Therapeutics Announces Completion of Mid-Cycle - GlobeNewswire
FDA Fast-Tracks Revolutionary DMD Heart Treatment as Capricor Clears Major Regulatory Hurdle - Stock Titan
Barclays PLC Has $1.24 Million Stock Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Stock Position Lessened by JPMorgan Chase & Co. - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Consensus Target Price from Analysts - Defense World
Wells Fargo & Company MN Sells 4,641 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ: CAPR) Stock Gained 34.46% Over A Month – Any Room To Run? - Marketing Sentinel
Capricor Therapeutics Inc (CAPR) shows promising results - uspostnews.com
Capricor Therapeutics Inc (CAPR) receives an Overweight rating from Piper Sandler - knoxdaily.com
Legal & General Group Plc Grows Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Capricor Therapeutics Inc’s Market Journey: Closing Weak at 12.83, Down -1.53 - DWinneX
Russell Investments Group Ltd. Grows Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc [NASDAQ: CAPR] Sees Increase in Stock Value - knoxdaily.com
Capricor Therapeutics Inc (NASDAQ:CAPR) Stock Holdings Increased by Geode Capital Management LLC - Defense World
13,280 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Alliancebernstein L.P. - Defense World
Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ... By GuruFocus - Investing.com Canada
Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges and Strategic Advancements - GuruFocus
Former Novartis Deal Chief Who Led 50+ Strategic Transactions Joins OmniAb Board - Stock Titan
Analysts Expect Breakeven For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Before Long - simplywall.st
Stock Traders Purchase High Volume of Capricor Therapeutics Call Options (NASDAQ:CAPR) - Defense World
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Benzinga
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable? - Yahoo
Wellington Management Group LLP Invests $565,000 in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Vanguard Group Inc. Purchases 700,243 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Corebridge Financial Inc. Has $251,000 Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
KLP Kapitalforvaltning AS Invests $91,000 in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
0.15%
자본화:
|
볼륨(24시간):